Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;34(11):e14081.
doi: 10.1111/ctr.14081. Epub 2020 Sep 30.

Beta-blocker therapy in heart transplant recipients: A review

Affiliations
Review

Beta-blocker therapy in heart transplant recipients: A review

Daniele Masarone et al. Clin Transplant. 2020 Nov.

Abstract

Beta-blockers are essential drugs for the treatment of many cardiovascular diseases, such as heart failure, acute and chronic ischemic heart disease, tachyarrhythmias, and hypertension. However, these drugs have not been used in cardiac transplant patients for many years owing to the fear that they could reduce cardiac output and functional capacity. In recent years, however, some evidence has shown that even in cardiac transplanted patients, β-blockers are useful and effective in the treatment of sinus tachycardia, supraventricular and ventricular tachyarrhythmias, left ventricular systolic dysfunction, and arterial hypertension. Furthermore, some data have shown that the use of β-blockers is associated with reduced mortality in heart transplant recipients. In this review, we summarize this evidence with particular emphasis on the practical aspects of the use of β-blockers in post-transplantation patients to promote the use of this important class of drugs in clinical practice.

Keywords: arrhythmias; heart rate; heart transplant; β-blockers.

PubMed Disclaimer

References

REFERENCES

    1. Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report-2014; focus theme: retransplantation. J Heart Lung Transplant. 2014;33:996-1008.
    1. Lindenfeld JoAnn, Page RL, Zolty R, et al. Drug therapy in the heart transplant recipient: part III: common medical problems. Circulation. 2005;111:113-117.
    1. Wilhelm MJ. Long-term outcome following heart transplantation: current perspective. J Thorac Dis. 2015;4:549-551.
    1. De Sutter J, Mendes M, Franco OH. Chapter 19 Cardioprotective drugs. In: Gielen S, De Backer G, Piepoli MF, Wood D, eds. The ESC Textbook of Preventive Cardiology, 2nd edn. United Kingdom: Oxford University Press; 2016.
    1. Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol. 2005;144:317-322.

Substances